Research & Development
Molecule Holdings' COVID-19 IgG and IgM Rapid Test authorised for distribution
2 April 2020 -

Molecule Holdings reported on Wednesday that it is now providing FDA-approved rapid COVID-19 test kits to medical professionals, first responders and law enforcement.

The COVID Care Rapid Test detects IgG and IgM antibodies to SARS-CoV-2 in human blood. It has a 91% clinical sensitivity rating and a 99% clinical specifity rating.

The testing kits are manufactured in an ISO-13485 certified facility of Pinnacle BioLabs, an FDA registered laboratory in Tennessee. They have undergone significant preliminary clinical testing.

Molecule Holdings explained that the COVID Care test is easy and resembles the tests diabetics use to test their blood sugar. The finger is pricked with the included lance, two drops of blood are added into the testing cassette, together with two drops of testing solution, and the results are ready in five minutes.



Related Headlines